B-cell lymphoma

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
ASH, ADC, EMA, Patient, Camptothecin, Research, Therapy, Cancer, Oncogene, Poster, Multiple myeloma, Hematology, PALO, Safety, Therapeutic index, IND, DLBCL, Prednisone, Mantle cell lymphoma, Tumor microenvironment, SMDC, Society, RNA, Venetoclax, Corporation, Spacecraft, SME, Salivary gland tumour, MCL1, Cohort, European Medicines Agency, PDX, B-cell lymphoma, University, HER2, Acute lymphoblastic leukemia, Myelodysplastic syndrome, PTCL, MYC, MCL, Neoplasm, CPT, Peripheral T-cell lymphoma, Small and medium-sized enterprises, CDK9, FDA, RNA polymerase II, NIH, Toxicity, Vaccine, Pharmaceutical industry, Fine chemical, Medical imaging, Rare-earth element, Cryptocurrency

PALO ALTO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “We continue to take a very disciplined approach to our portfolio, focusing our resources on our two lead programs, VIP943 and VIP236.
  • We will present new data on robust preclinical activity at the 65th American Society for Hematology Meeting (ASH 2023) in December.
  • Collaborators from the University of Calgary will present a poster at ASH 2023 showing preclinical activity in pediatric leukemia.
  • For the quarter ended September 30, 2023, Vincerx reported a net loss of approximately $9.7 million, or $0.46 per share, compared to a net loss of approximately $16.9 million, or $0.80 per share, for the quarter ended September 30, 2022.

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Safety, Therapy, Workforce, Investment, Clinical trial, B-cell lymphoma, Rituximab, Depreciation, Patient, Research, FDA, Autoimmune disease, G&A, SLE, Hematology, Lupus Research Alliance, Lupus nephritis, Cytarabine, Cancer, R, Kinetics, AML, American Society of Hematology, Lupus, Society, NHL, Poster, LD, NK, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Rare-earth element, LN

In June 2023, Nkarta reported updated clinical data from its Phase 1 clinical trial evaluating NKX101 in patients with relapsed or refractory (r/r) AML.

Key Points: 
  • In June 2023, Nkarta reported updated clinical data from its Phase 1 clinical trial evaluating NKX101 in patients with relapsed or refractory (r/r) AML.
  • In October 2023, Nkarta announced the opening of a new cohort in its Phase 1 study of NKX019 in r/r NHL.
  • As of September 30, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $278.4 million.
  • Net loss was $25.6 million, or $0.52 per basic and diluted share, for the third quarter of 2023.

CALQUENCE (Acalabrutinib) Emerging Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Science, Pharmaceutical, Research, Clinical Trials, Carboplatin, Chemotaxis, Waldenström macroglobulinemia, AstraZeneca, BTK, MCL, Rituximab, B-cell lymphoma, Patient, Ifosfamide, ABC, SWOT, EU4, Etoposide, Follicular lymphoma, Acalabrutinib, Waldenström, RICE, CLL, Axicabtagene ciloleucel, Risk management, Pharmaceutical industry, DLBCL, Phase

The "CALQUENCE Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CALQUENCE Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about CALQUENCE for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the CALQUENCE market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CALQUENCE in DLBCL.

Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

Retrieved on: 
Tuesday, December 12, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Arm, Safety, Senior, Hope, Hypogammaglobulinemia, Ageing, ASH, University, EFS, B-cell lymphoma, Patient, Abstract, PFS, DOR, Follicular lymphoma, Lymphoma, DSS, Subgroup analysis, Standard of care, ORR, MD, Survival, Death, HR, Doctor of Philosophy, MD Anderson Cancer Center, Cancer, SOC, OS, Knowledge, Society, Confidence interval, Pharmaceutical industry, Axicabtagene ciloleucel

In this post hoc analysis of ZUMA-1, with up to six years of follow-up, the five-year long-term lymphoma-related event-free survival (LREFS) was used as a measure to explore Yescarta’s curative potential.

Key Points: 
  • In this post hoc analysis of ZUMA-1, with up to six years of follow-up, the five-year long-term lymphoma-related event-free survival (LREFS) was used as a measure to explore Yescarta’s curative potential.
  • Yescarta had long-term LREFS in a substantial proportion of patients, with a five-year rate of 34% (57% among patients who achieved a CR).
  • Among patients who had a CR to therapy, the leading risks of death were reasons other than progression or adverse events after month 24 post-infusion.
  • “We are encouraged by these data, particularly the continued durable response and long-term survival in these patient populations that speak to the potentially curative benefit of this therapy.

Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, BCL2, Fever, MYC, Progression-free survival, ASH, Aes, CRS, EFS, B-cell lymphoma, Headache, Cytopenia, Non-Hodgkin lymphoma, Patient, Abstract, PFS, DOR, BCL6, Histology, ORR, MD, Survival, Doctor of Philosophy, Drug, Society, OS, Confidence interval, Axicabtagene ciloleucel, SVP, Cytokine release syndrome, Pharmaceutical industry

“Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.

Key Points: 
  • “Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center.
  • “This is particularly true of patients with double- or triple-hit histology, who have a median survival of under a year with standard treatment.
  • Prolonged cytopenias of any grade (present Day ≥30 post-infusion) occurred in 9 patients (n=7 neutrophil count decreased) and were resolved by data cutoff.
  • Among treated patients, the in vivo Yescarta expansion and persistence profiles are consistent with previous observations.

New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma

Retrieved on: 
Monday, December 11, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Doxorubicin, Safety, Lenalidomide, Progression-free survival, Bone marrow, ASH, CRS, Disease, DLBCL, Prednisone, B-cell lymphoma, Rituximab, Patient, Roche, PFS, ROG, Follicular lymphoma, Phases of clinical research, Polatuzumab vedotin, Exposition, Vincristine, GemOx, Cyclophosphamide, Society, OS, Cytokine release syndrome, HIV disease progression rates, Lymphoma, Fine chemical, Pharmaceutical industry, Medical device, Mosunetuzumab, Genentech, Phase, Nature Medicine

Additionally, new early-phase data of novel Columvi or Lunsumio combination regimens support ongoing investigation in Phase III studies in earlier lines of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Key Points: 
  • Additionally, new early-phase data of novel Columvi or Lunsumio combination regimens support ongoing investigation in Phase III studies in earlier lines of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
  • After a median follow-up of 32 months, 55% of patients with a complete response (CR) were in remission at 24 months.
  • Data showed that 83.3% of patients achieved a complete metabolic response (95% CI: 62.6-95.3), and responses were ongoing at data cut-off.
  • The data support further investigation of this SC formulation of Lunsumio and highlight its potential as a tailored monotherapy or combination outpatient therapy for FL, including in community practices.

Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, HKEX, Rituximab, Lenalidomide, Toxicity, Treatment, Progression-free survival, Lymphoid leukemia, MCL, ASH, Aes, Refractory, Bleeding, Patient, Abstract, PFS, Impact, TLS, POLARIS, MRD, DOR, Pharmacokinetics, OLR, Atrial fibrillation, Medicine, SSE, ORR, Diarrhea, Cancer, Peking Union Medical College, Zhongshan Hospital, Fudan University, CRR, Infrared spectroscopy correlation table, Society, TTR, Relapse, B-cell lymphoma, Hospital, Pharmaceutical industry, Vaccine, Medical imaging, Management, Safety

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
  • The study of orelabrutinib’s regimen in patients with untreated mantle cell lymphoma (MCL) was selected as an oral presentation.
  • The overall response rate (ORR) was 100%, and the complete response rate (CRR) was 76.2%.
  • This retrospective data suggests that orelabrutinib in combination with rituximab has an encouraging anti-tumor activity in MZL, with a favorable safety profile.

Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

Retrieved on: 
Sunday, December 10, 2023
Oncology, Health, Technology, Health Technology, Software, Pharmaceutical, Biotechnology, Webcast, Cytokine, Decitabine, Safety, CDC7, Lymphoid leukemia, ASH, Acute myeloid leukemia, Harmonic pitch class profiles, B-cell lymphoma, Patient, Abstract, NF, Pharmacokinetics, Therapy, Venetoclax, Chronic lymphocytic leukemia, Significance, Trial of the century, Human, MALT1, AML, Potent, Cancer, Society, Myelodysplastic syndrome, NHL, CLL, Pharmaceutical industry, Vaccine

The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.

Key Points: 
  • The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.
  • The company will report additional data from the healthy subject study at its Pipeline Day on December 14, 2023.
  • “The pharmacological data for SGR-1505 and SGR-2921 demonstrate that our development candidates have favorable, differentiated profiles with best-in-class potential,” stated Karen Akinsanya, Ph.D., president of R&D therapeutics at Schrödinger.
  • “Our progress within these programs further validates our computational approach to designing therapies with the potential to address the limitations of current treatments.

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Retrieved on: 
Saturday, December 9, 2023
Oncology, Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Tumor-associated macrophage, Associate, Toxicity, Weill Cornell Medicine, Progression-free survival, ASH, IND, Immunosuppression, Clinical trial, B-cell lymphoma, Patient, Tumor microenvironment, Pediatric Hematology and Oncology, Pharmacology, Lymph, Lymphatic system, TME, Therapy, Cancer, CD47, CMO, Drug resistance, 65th Street Yard, Doctor of Philosophy, Chemokine, Society, Overalls, Pharmaceutical industry, Vaccine, DLBCL, Hematology, Lymphoma, MD

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.
  • The new preclinical data covers results for SC-2882, Scenic’s first-in-class QPCTL inhibitor, as a potential new treatment approach for diffuse large B-cell lymphoma (DLBCL).
  • SC-2882 targets QPCTL and thereby inhibits the CD47-SIRPα “don’t eat me” checkpoint and lowers immune suppression in the tumor microenvironment.
  • Analysis of DLBCL patient datasets revealed that QPCTL expression negatively correlates with overall and progression-free survival.

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Pharmaceutical, Health, ATRA, Epstein–Barr virus, TCR, Gene editing, Phenotype, Lymphoid leukemia, ASH, IND, Risk, Northwest Biotherapeutics, B-cell lymphoma, HCT, Head, Patient, CD19, Autoimmune disease, Acute lymphoblastic leukemia, HLA, Cancer, Survival, CD20, EBV, Society, Cell, Vaccine, Atara

Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.

Key Points: 
  • Findings support ATA3431 advancement into clinical testing, initially focused on the treatment of B-cell malignancies.
  • The data will be presented in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place December 9-12, 2023, in San Diego.
  • ATA3431 also incorporates the clinically validated 1XX costimulatory domain that enhances stemness and modulates exhaustion to extend functional persistence.
  • Compared to an autologous CD20/CD19 CAR-T benchmark, the ATA3431 preclinical data demonstrate potent antitumor activity, long-term persistence, and superior tumor growth inhibition.